Pharmaceutical Technology on MSN13h
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot
Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...
Transcript: Are Musk’s ties jeopardising Starlink?
Rafe Uddin So Starlink’s role in a number of European countries means that it’s seen as an easy target, given Musk’s proximity to Trump. There are also fears about a peace settlement between Russia ...
Novo Nordisk Is Licensing a Chinese Weight-Loss Drug. Why the Stock Is Down.
Novo Nordisk said Monday that it had entered into a license agreement with a Chinese company developing a competitor to ...
Novo Nordisk Strikes $2B Deal for Obesity Drug
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Novo Nordisk Signs $2 Billion Deal for Experimental Obesity Drug
Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...
The Facts1d
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
GUANGDONG, CHINA AND BAGSVÆRD, DENMARK - Media OutReach Newswire - 24 March 2025 - The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that ...
Kyivstar can grow in 'distressed' US market, VEON boss says ahead of IPO
VEON , reported a 14.6% jump in its annual revenue on Thursday, despite a Russian cyberattack in Ukraine and political unrest in Bangladesh affecting the telecoms group's operations.